CONMED Corporation (CNMD)

Return on equity (ROE)

		Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Net income	US$ in thousands	64,459	-80,582	62,542	9,517	28,620
Total stockholders’ equity	US$ in thousands	834,222	745,545	785,435	709,038	710,467
ROE		7.73%	-10.81%	7.96%	1.34%	4.03%

December 31, 2023 calculation

ROE = Net income ÷ Total stockholders’ equity
= $64,459K ÷ $834,222K
= 7.73%

Conmed Corp.'s return on equity (ROE) has varied over the past five years. In 2023, the company's ROE stood at 7.73%, marking a positive increase compared to the previous year where it was -10.81%, indicating a significant improvement in the company's profitability and efficiency in generating returns for its shareholders.

Looking further back, in 2022, the negative ROE of -10.81% suggests that the company experienced a period of underperformance and inefficiency in its operations, resulting in a net loss for shareholders. However, in 2021, the company rebounded with an ROE of 7.96%, indicating a return to profitability and a positive trend in generating shareholder value.

In 2020 and 2019, Conmed Corp.'s ROE was 1.34% and 4.03%, respectively, showing modest profitability levels in those years. Overall, the fluctuating ROE figures indicate that Conmed Corp. has experienced both challenges and successes in its ability to utilize shareholders' equity effectively to generate profits throughout the analyzed period.